stockrowViatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
- Revenue
- −0.28%
- EPS
- −154.6%
- Free cash flow
- +38.8%
- Total debt
- −89.4%
Quarter to September 2026, against a year earlier
Follow VTRS
Alert me
Viatris Inc. (VTRS) Free cash flow
Viatris Inc.'s free cash flow for fiscal 2025 was $1.9B, down 56.6% from $4.5B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.4B. Over the past ten years it has ranged from $552.7M (fiscal 2020) to $4.5B (fiscal 2024); the current reading is higher than 64% of that period. Viatris Inc. ranks 3rd of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.9B | (56.58%) |
| FY2024 | $4.5B | 59.29% |
| FY2023 | $2.8B | 9.10% |
| FY2022 | $2.6B | 1.74% |
| FY2021 | $2.5B | 356.99% |
| FY2020 | $552.7M | (61.23%) |
| FY2019 | $1.4B | 21.29% |
| FY2018 | $1.2B | (6.37%) |
| FY2017 | $1.3B | (3.19%) |
| FY2016 | $1.3B | 13.83% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $896.5M | 166.66% |
| Jun 2026 | $336.2M | 25.45% |
| Mar 2026 | $268.0M | (58.15%) |
| Dec 2025 | $640.4M | (0.87%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| VTRS Viatris Inc. | $2.4B |
| ZTS Zoetis Inc. compare | $2.3B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.3B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.0B |
| UTHR United Therapeutics Corporation compare | $867.2M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| ALKS Alkermes plc compare | $228.4M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement